A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II study to evaluate the effectiveness of study drug sunitinib malate in
patients with recurrent and/or metastatic adenoid cystic carcinomas of the salivary gland.
There currently is not standard of care for this type of cancer and it has hoped that
sunitinib will have antitumor effects on patients with this type of cancer.